• Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

    1 month ago - By News Medical

    Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.
    Read more ...